
Are GLP-1s causing blindness? Novo Nordisk, Eli Lilly face lawsuits in US
The story in brief
A potential safety signal linking GLP-1 drugs to NAION, a condition causing sudden vision loss, was first reported in 2024. Researchers have examined the link but found no established causation. The FDA does not require NAION warnings, while the EMA and TGA do. Companies like Novo Nordisk and Eli Lilly continue to monitor safety, disputing lawsuit claims.